Abstract
Posterior reversible encephalopathy syndrome (PRES) is an acute central nervous system disorder characterized by reversible brain vasogenic edema.
We report here a new case of a nine-year-old boy with B-cell acute lymphoblastic leukemia (B-ALL) who developed PRES secondary to induction chemotherapy including dexamethasone (dexamethasone®), vincristine (oncovin®), daunorubicin (adriblastine®) and intrathecal injection. Cerebral magnetic resonance imaging (MRI) showed high signal intensity on T2 at cortical and sub cortical region of parieto-frontal and parieto-occipital lobes. The patient was put under sodium valproate (depakine®) and we decided to continue dexamethasone (dexamethasone®) and daunorubicin (adriblastine®) injection. The MRI, after four weeks, was normal. So, we resumed vincristine (oncovin®) and we started L-asparaginase injections. Then, the outcome was favorable.
The treatment of PRES is based on the withdrawal of the triggering factor to avoid the risk of irreversible lesions. But, due to the severity of leukemia the discontinuation of chemotherapy is difficult because of the risk of disease progression.
Keywords: Chemotherapy, diagnosis, etiopathogeny, leukemia, PRES, treatment.
Current Drug Safety
Title:Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Volume: 10 Issue: 2
Author(s): Wala Ben Kridis, Moez Mdhaffer, Yosr Hentati, Fatma Kammoun, Abir Milad, Sondes Haddar, Khaireddine Ben Mahfoudh, Chahinez Triki and Moez Elloumi
Affiliation:
Keywords: Chemotherapy, diagnosis, etiopathogeny, leukemia, PRES, treatment.
Abstract: Posterior reversible encephalopathy syndrome (PRES) is an acute central nervous system disorder characterized by reversible brain vasogenic edema.
We report here a new case of a nine-year-old boy with B-cell acute lymphoblastic leukemia (B-ALL) who developed PRES secondary to induction chemotherapy including dexamethasone (dexamethasone®), vincristine (oncovin®), daunorubicin (adriblastine®) and intrathecal injection. Cerebral magnetic resonance imaging (MRI) showed high signal intensity on T2 at cortical and sub cortical region of parieto-frontal and parieto-occipital lobes. The patient was put under sodium valproate (depakine®) and we decided to continue dexamethasone (dexamethasone®) and daunorubicin (adriblastine®) injection. The MRI, after four weeks, was normal. So, we resumed vincristine (oncovin®) and we started L-asparaginase injections. Then, the outcome was favorable.
The treatment of PRES is based on the withdrawal of the triggering factor to avoid the risk of irreversible lesions. But, due to the severity of leukemia the discontinuation of chemotherapy is difficult because of the risk of disease progression.
Export Options
About this article
Cite this article as:
Kridis Ben Wala, Mdhaffer Moez, Hentati Yosr, Kammoun Fatma, Milad Abir, Haddar Sondes, Mahfoudh Ben Khaireddine, Triki Chahinez and Elloumi Moez, Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue, Current Drug Safety 2015; 10 (2) . https://dx.doi.org/10.2174/1574886309666140610160851
DOI https://dx.doi.org/10.2174/1574886309666140610160851 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Insights into the Biology of 1-Antitrypsin and its Role in Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Developmental Immunotoxicity (DIT) in Drug Safety Testing: Matching DIT Testing to Adverse Outcomes and Childhood Disease Risk
Current Drug Safety Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Treatment Outcome of Three Female Adolescents with Borderline Personality Disorder
Adolescent Psychiatry Controlled Somatic and Germline Copy Number Variation in the Mouse Model
Current Genomics Influence of Pulsing Electromagnetic Field Therapy on Gene Expression in Muscle Cells, Peripheral Circulation, and Metabolic Factors in Aging Adults
Current Chemical Biology Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Safety Considerations Associated with Development and Clinical Application of Lentiviral Vector Systems for Gene Transfer
Current Genomics Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma
Current Cancer Drug Targets Molecular Cytogenetics of Autism
Current Genomics Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Current Cardiology Reviews The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters <i>In Silico</i> Structural and Functional Analysis of <i>Bacillus</i> Uricases
Current Proteomics Aging and Oral Health: Effects in Hard and Soft Tissues
Current Pharmaceutical Design The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science Biological Rationale for Regular Physical Exercise as an Effective Intervention for the Prevention and Treatment of Depressive Disorders
Current Pharmaceutical Design The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry Long-Term Survivors of Cancer in Childhood and Adolescence
Current Pediatric Reviews World Health Organization Classification of Myelodysplastic Syndromes
Current Pharmaceutical Design Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry